BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21435151)

  • 21. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
    Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
    Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
    Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
    Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
    Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
    Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
    Zier KS; Salvadori S; Cronin KC; Gansbacher B
    Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis.
    George JF; Gooden CW; Guo L; Kirklin JK
    J Heart Lung Transplant; 2008 Jun; 27(6):616-22. PubMed ID: 18503960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.